Results: Ketoconazole significantly decreased the MICs of levofloxacin, ciprofloxacin, norfloxacin, and EtBr (a substrate for efflux pump) by 8 to 1024 Abstract
The use of potent inhibitors of CYP3A such as ketoconazole has been explored to reduce the clearance of CYP3A substrates, thereby resulting in smaller dose requirements; however, the impact of CYP3A inhibition on interindividual variability has not been well
0 mg
Coadministration of ketoconazole may result in increased plasma concentrations of
Ketoconazole foam or gel is used to treat seborrheic dermatitis (scaly areas on your skin or scalp)
Results: Ketoconazole significantly decreased the MICs of levofloxacin, ciprofloxacin, norfloxacin, and EtBr (a substrate for efflux pump) by 8 to 1024-fold (P<0
Ketoconazole is a potent inhibitor of hepatic P450 enzymes; thus dosage adjustments may be necessary to prevent adverse drug interactions
If use is unavoidable, reduce encorafenib dose to 150 mg/day if current dose is 450 mg/day and 75 mg/day if current dose is 150-300mg/day
0, released under the GPLv2 license by the Open Systems Pharmacology community, www
It’s available as an oral tablet, topical cream, topical foam, shampoo, and topical gel
Scientific Reports (2019) Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second Ketoconazole (Topical Route) Merative, Micromedex
Other P-450 enzymes that are inhibited by ketoconazole include 1alpha-hydroxylase and 24-hydroxylase, which metabolize vitamin D
pale skin
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential